# Wyndly **Source:** https://geo.sig.ai/brands/wyndly **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** wyndly.com **Last Updated:** 2026-04-14 ## Summary Telehealth allergy immunotherapy with at-home test kits and sublingual drops by mail; making multi-year desensitization treatment accessible without clinic visits. ## Company Overview Wyndly is a digital telehealth platform providing allergy immunotherapy treatment by mail, enabling patients to begin long-term allergy desensitization without the time commitment of in-office allergy shot clinics. Founded in 2020 and headquartered in Wilmington, Delaware, Wyndly's service involves an at-home allergy test kit, virtual consultation with an allergist, and custom-formulated sublingual immunotherapy drops delivered to the patient's home — making a years-long treatment process dramatically more convenient than traditional allergy shot protocols. The company raised $12 million in Series A funding in 2022, backed by BoxGroup, Cota Capital, and others, targeting the millions of allergy sufferers who either cannot access allergy specialists or cannot commit to the twice-weekly clinic visits required for traditional subcutaneous immunotherapy. Wyndly's sublingual drops (administered under the tongue at home) avoid the need for in-office injections while still providing the desensitization mechanism that builds long-term allergy tolerance. In 2025, Wyndly operates in the rapidly growing digital health allergy space alongside Curex, Allermi, and traditional allergy practices offering telemedicine. The company's async telehealth model — patients complete questionnaires, receive test results online, consult via video, and receive drops by mail — maximizes accessibility for busy adults with seasonal or perennial allergies. Wyndly serves patients in most US states and has expanded its panel of board-certified allergists to accommodate demand. The company's 2025-2026 focus includes expanding to pet and food allergy protocols and deepening insurance coverage acceptance to reduce out-of-pocket costs. ## Frequently Asked Questions ### What is Wyndly? Wyndly is a telepharmacy provider founded in 2020 that offers personalized allergy medicines through at-home testing and sublingual immunotherapy drops. The company is backed by Y Combinator (W21 batch) and based in Centennial, Colorado. ### What services does Wyndly offer? Wyndly provides at-home allergy testing, sublingual immunotherapy drops, personalized allergy treatment, and telepharmacy services. Their allergy drop subscription is available for $99/month. ### Who can benefit from Wyndly's services? Wyndly targets the 60 million Americans who suffer from allergies and are seeking convenient, personalized treatment options. ### When was Wyndly founded and by whom? Wyndly was founded in 2020 by Dr. Manan Shah, an ENT surgeon who serves as Chief Medical Officer, and Aakash Shah, who serves as CEO. ### Where is Wyndly located? Wyndly is based in Centennial, Colorado. ### How much funding has Wyndly raised? Wyndly has raised $2.12 million in total funding over 2 rounds, including a $2 million Series A on February 8, 2023. The Series A was led by Y Combinator, with participation from Goodwater Capital, Civilization Ventures, Sweater, and angel investors. ### What are Wyndly's recent achievements? Wyndly generated $1 million in revenue in 2022 and doubled its sales in 2024. The company is backed by Y Combinator and serves the allergy treatment market. ### What is Wyndly's treatment approach? Wyndly uses sublingual immunotherapy drops as an alternative to traditional allergy shots, providing personalized treatment based on at-home allergy testing results. This telepharmacy approach allows patients to receive allergy care remotely. ### How much does Wyndly cost? Wyndly's allergy drop subscription costs $99/month (approximately $594 for 6 months). The allergy test costs $200 if you don't become a patient, but is free for patients who continue with treatment. ### What is Wyndly's latest funding news? Wyndly's most recent funding round was a $2 million Series A on February 8, 2023, led by Y Combinator with participation from Goodwater Capital, Civilization Ventures, and Sweater. This brought their total funding to $2.12 million across 2 rounds. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*